[go: up one dir, main page]

MX2017014075A - Composiciones de peptido y metodos de uso. - Google Patents

Composiciones de peptido y metodos de uso.

Info

Publication number
MX2017014075A
MX2017014075A MX2017014075A MX2017014075A MX2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A
Authority
MX
Mexico
Prior art keywords
methods
peptide compositions
portids
photoreceptors
fas
Prior art date
Application number
MX2017014075A
Other languages
English (en)
Other versions
MX387317B (es
Inventor
G Besirli Cagri
J Bridges Alexander
K Freshley John
A Hunke William
L Johnson Linda
X Smith Francis
Sylvain Ethan
N Zacks David
Original Assignee
Onl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onl Therapeutics Inc filed Critical Onl Therapeutics Inc
Publication of MX2017014075A publication Critical patent/MX2017014075A/es
Publication of MX387317B publication Critical patent/MX387317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente solicitud se proveen composiciones que incluyen póptidos, preparaciones farmacóuticas de los mismos, y métodos para prevenir muerte de fotorreceptor con las mismas y proteger las cólulas de la retina, incluyendo, pero sin limitarse a, fotorreceptores y epitelio pigmentario retiniano, contra apoptosis mediada por Fas o TRAIL.
MX2017014075A 2015-05-01 2016-04-29 Composiciones de peptido y metodos de uso. MX387317B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
MX2017014075A true MX2017014075A (es) 2018-07-06
MX387317B MX387317B (es) 2025-03-18

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014075A MX387317B (es) 2015-05-01 2016-04-29 Composiciones de peptido y metodos de uso.

Country Status (21)

Country Link
US (5) US10508134B2 (es)
EP (3) EP3288379B1 (es)
JP (2) JP6884755B2 (es)
KR (2) KR20240046280A (es)
CN (2) CN113651873B (es)
AU (1) AU2016258837B2 (es)
CA (1) CA2984154A1 (es)
CY (1) CY1124911T1 (es)
DK (1) DK3288379T3 (es)
EA (2) EA035293B1 (es)
ES (1) ES2906173T3 (es)
HR (1) HRP20220138T1 (es)
HU (1) HUE057883T2 (es)
LT (1) LT3288379T (es)
MX (1) MX387317B (es)
PL (1) PL3288379T3 (es)
PT (1) PT3288379T (es)
RS (1) RS62866B1 (es)
SI (1) SI3288379T1 (es)
SM (1) SMT202200069T1 (es)
WO (1) WO2016178993A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113651873B (zh) * 2015-05-01 2025-09-02 Onl医疗股份有限公司 肽组合物和使用方法
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
KR20220118499A (ko) * 2019-12-18 2022-08-25 셀라 테라퓨틱스, 엘엘씨 신경영양제, 세포자멸 신호전달 단편 억제제(FAS) 또는 FAS 리간드(FASL) 억제제, 종양 괴사 인자-α(TNF-α) 또는 TNF 수용체 억제제, 미토콘드리아 펩티드, 올리고뉴클레오티드, 케모카인 억제제 또는 시스테인-아스파틱 프로테아제 억제제를 포함하는 약물 전달 시스템
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
JP2024525805A (ja) * 2021-07-13 2024-07-12 オーエヌエル セラピューティクス，インク． 眼の疾患および障害における視機能を改善するための方法および組成物
US20250163131A1 (en) * 2021-12-27 2025-05-22 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
WO2024220669A1 (en) * 2023-04-19 2024-10-24 Onl Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US20080280834A1 (en) 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
CA2708549C (en) * 2007-12-21 2014-04-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
EP2403937B1 (en) 2009-03-03 2015-05-06 The Regents of the University of Michigan Use of met peptide for inhibiting photoreceptor apoptosis
CA2756864A1 (en) * 2009-03-30 2010-10-07 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase)-inhibitory peptide, and use of the peptide
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
CA2838474A1 (en) * 2011-06-06 2012-12-13 Kineta One, Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
CA2861543C (en) 2012-01-18 2022-05-31 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
BR112014031923B1 (pt) * 2012-06-21 2022-02-08 Daewoong Pharmaceutical Co., Ltd. Uso de uma composição compreendendo pelo menos um tnfri modificado ou fragmento tnfri modificado, uso de uma formulação tópica e uso de uma composição
AU2013337702A1 (en) * 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
CN107533048A (zh) 2015-02-05 2018-01-02 美国免疫阵列公司 用于诊断脑损伤或神经退行性变的方法和组合物
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
CN113651873B (zh) * 2015-05-01 2025-09-02 Onl医疗股份有限公司 肽组合物和使用方法
CN110177577A (zh) 2016-07-05 2019-08-27 马萨诸塞大学 Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Also Published As

Publication number Publication date
HUE057883T2 (hu) 2022-06-28
WO2016178993A1 (en) 2016-11-10
AU2016258837A1 (en) 2017-11-09
PT3288379T (pt) 2022-02-08
KR102652804B1 (ko) 2024-04-01
US20180291062A1 (en) 2018-10-11
CA2984154A1 (en) 2016-11-10
CN107708416A (zh) 2018-02-16
CY1124911T1 (el) 2023-01-05
JP2021120400A (ja) 2021-08-19
HRP20220138T1 (hr) 2022-05-27
EP3997981A1 (en) 2022-05-18
BR112017023479A2 (pt) 2018-07-24
CN113651873B (zh) 2025-09-02
US11597749B2 (en) 2023-03-07
US20250346631A1 (en) 2025-11-13
EP3288379A4 (en) 2018-10-24
US20230287052A1 (en) 2023-09-14
US10508134B2 (en) 2019-12-17
EA202090184A2 (ru) 2020-05-31
ES2906173T3 (es) 2022-04-13
US20210094985A1 (en) 2021-04-01
EA202090184A3 (ru) 2020-07-31
LT3288379T (lt) 2022-02-25
SMT202200069T1 (it) 2022-03-21
EA035293B1 (ru) 2020-05-26
AU2016258837B2 (en) 2020-12-03
MX387317B (es) 2025-03-18
EP3288379A1 (en) 2018-03-07
RS62866B1 (sr) 2022-02-28
EP4623925A2 (en) 2025-10-01
KR20170140383A (ko) 2017-12-20
JP6884755B2 (ja) 2021-06-09
US20200123201A1 (en) 2020-04-23
PL3288379T3 (pl) 2022-03-07
SI3288379T1 (sl) 2022-06-30
KR20240046280A (ko) 2024-04-08
CN113651873A (zh) 2021-11-16
DK3288379T3 (da) 2022-02-07
US12258425B2 (en) 2025-03-25
HK1251979A1 (zh) 2019-05-10
EA201792399A1 (ru) 2018-05-31
CN107708416B (zh) 2021-06-29
JP2018514590A (ja) 2018-06-07
US10829518B2 (en) 2020-11-10
EP3288379B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
MX2017014075A (es) Composiciones de peptido y metodos de uso.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2018014869A (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2017001512A (es) Compuestos activos hacia bromodominios.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
EA201691582A1 (ru) Новые фармацевтические препараты
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX378108B (es) Anticuerpos anti-met y composiciones.
MX2016011176A (es) Polipeptidos fhbp meningococicos modificados.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
WO2016164744A8 (en) Protective action of lutein against blue light on human skin cell lines
IL254617A0 (en) Improved assays for the potential of retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
EP3193867A4 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
MA40369A (fr) Applications de l'extrait de cistanche tubulosa dans la préparation d'un médicament ou produit de protection les cellules de l'œil
HK40066729A (zh) 改进的人视网膜色素(rpe)细胞和感光祖细胞的效能测定
HK40066729B (zh) 改进的人视网膜色素(rpe)细胞和感光祖细胞的效能测定